• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Oncology: So, what's the deal.........









































































they are adding mirrored reps in about 20-30 territory's that are considered volume potential. One rep will be 89% haloven the other rep 80% lemvina
Oh joy. Mirrored reps. That always works out perfectly. What once office with limited access already wouldn't want to see 2 Eisai reps instead of just one.
The clowns running Eisai oncology don't have one original thought between them..